Abstract
Background: Dose-dense chemotherapy (DDCT) is a standard treatment for patients with high-risk breast cancer. Although there are numerous reports regarding DDCT, it is unclear whether sequential DDCT is effective or feasible as preoperative treatment for Japanese patients. We evaluated the efficacy and safety of neoadjuvant DDCT for patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Methods: This retrospective study evaluated 39 patients with breast cancer, who were preoperatively treated with anthracyclinecontaining regimens and taxanes. According to the chemotherapy regimens patients were divided into the DDCT group (ddgroup) and the conventional chemotherapy (CCT) group (q3w-group). The efficacy of neoadjuvant chemotherapy was evaluated based on the pathological complete response (pCR) rate. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events version 5.0.
Results: There were no apparent differences in tumor stage, histopathological subtype, or surgical procedure. There was not significant difference in the pCR rate (dd-group, 17.6%; q3w-group, 22.7%). Three-year disease-free survival rates were similar in two groups. The rates of dose reduction, delay of treatment, and discontinuation of treatment in the two groups did not differ to a statistically significant extent. There were no significant differences in the adverse events of the two groups.
Conclusion: The pCR rate for DDCT was similar to that of CCT. DDCT may be feasible for Japanese breast cancer patients.
